Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Acquired by Nordea Investment Management AB

Nordea Investment Management AB increased its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 4.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 279,714 shares of the company’s stock after purchasing an additional 12,851 shares during the period. Nordea Investment Management AB’s holdings in Amphastar Pharmaceuticals were worth $10,386,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in AMPH. Aurora Investment Counsel lifted its holdings in shares of Amphastar Pharmaceuticals by 0.4% in the 3rd quarter. Aurora Investment Counsel now owns 54,698 shares of the company’s stock valued at $2,654,000 after buying an additional 232 shares during the period. GAMMA Investing LLC raised its position in Amphastar Pharmaceuticals by 70.0% in the third quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock worth $32,000 after acquiring an additional 273 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Amphastar Pharmaceuticals by 20.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock valued at $85,000 after acquiring an additional 301 shares during the period. Point72 Asia Singapore Pte. Ltd. boosted its position in shares of Amphastar Pharmaceuticals by 53.4% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after purchasing an additional 398 shares in the last quarter. Finally, nVerses Capital LLC boosted its position in shares of Amphastar Pharmaceuticals by 18.2% during the 3rd quarter. nVerses Capital LLC now owns 2,600 shares of the company’s stock worth $126,000 after purchasing an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Price Performance

Amphastar Pharmaceuticals stock opened at $36.63 on Thursday. The firm has a market capitalization of $1.76 billion, a PE ratio of 12.21, a P/E/G ratio of 0.87 and a beta of 0.82. Amphastar Pharmaceuticals, Inc. has a 52 week low of $34.69 and a 52 week high of $58.64. The firm’s 50-day simple moving average is $43.31 and its 200 day simple moving average is $44.28. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82.

Analyst Ratings Changes

Several analysts recently commented on the stock. StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Wells Fargo & Company began coverage on shares of Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price target for the company. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $60.33.

Insiders Place Their Bets

In related news, Director Richard K. Prins sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $43.77, for a total value of $437,700.00. Following the sale, the director now owns 30,471 shares of the company’s stock, valued at approximately $1,333,715.67. This represents a 24.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Rong Zhou sold 7,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $44.42, for a total value of $310,940.00. Following the transaction, the executive vice president now directly owns 118,469 shares of the company’s stock, valued at $5,262,392.98. The trade was a 5.58 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 41,533 shares of company stock worth $1,987,482. Insiders own 27.10% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.